United States Department of Veterans Affairs
Research Advisory Committee on Gulf War Veterans' Illnesses

Research Update - December 2006

The following journal articles were distributed for review in December 2006.  You can access the article's abstract by copying the paper title and pasting it into the search bar of the PubMed website, linked here. 


Research Relevant to Gulf War Service and Exposures
 
1. Changes of acetylcholinesterase activity in different rat brain areas following intoxication with nerve agents: Biochemical and histochemical study.  (Bajgar J, et al.  Chem Biol Interact.  Oct 24, 2006; [Epub ahead of print])
 
2. To the Editor - Deployment to the Iraq War and neuropsychological sequelae.  (Boiko P.  JAMA.  Dec 13, 2006; 296(22): 2678; author reply 2679-2680)
 
3. Neuromuscular therapeutics by RNA-targeted suppression of AChE Gene Expression.  (Dori A, Soreq H.  Ann N Y Acad Sci.  Oct 2006; 1082: 77-90)
 
4. WHO suppressed evidence on effects of depleted uranium, expert says.  (Dyer O.  BMJ.  Nov 11, 2006; 333(7576): 990)
 
5. Army research needs for automated neuropsychological tests: Monitoring soldier health and performance status.  (Friedl KE, et al.  Arch Clin Neuropsychol.  Nov 24, 2006; [Epub ahead of print])
 
6. Relative impact of adverse events and screened symptoms of posttraumatic stress disorder and depression among active duty soldiers seeking mental health care.  (Gahm GA , et al.  J Clin Psychol.  Nov 17, 2006; [Epub ahead of print])
 
7. Effects of low-level inhalation exposure to cyclosarin on learned behaviors in Sprague-Dawley rats.  (Genovese RF, et al.  J Toxicol Environ Health A.  Dec 2006; 69(24): 2167-2180)
 
8. Evaluation of cognitive and biochemical effects of low-level exposure to sarin in rhesus and African green monkeys.   (Genovese RF, et al.  Toxicology.  Nov 23, 2006; [Epub ahead of print])
 
9. Enhanced cortisol suppression to dexamethasone associated with Gulf War deployment.   (Golier JA, et al.  Psychoneuroendocrinology.  Oct 14, 2006; [Epub ahead of print]
 
10. Development of methods to measure humoral immune responses against selected antigens in the common marmoset (Callithrix jacchus) and the effect of pyridostigmine bromide administration.   (Griffiths GD, et al.  Int Immunopharmacol.  Dec 2006; 6(12): 1755-1764)
 
11. Effect of acetaminophen administration to rats chronically exposed to depleted uranium.  (Gueguen Y, et al.  Toxicology.  Oct 17, 2006; [Epub ahead of print])
 
12. To the Editor – Deployment to the Iraq war and neuropsychological sequelae.  (Hoge CW.  JAMA.  Dec 13, 2006; 296(22): 2678-2679; author reply 2679-2680)
 
13. Multiple vaccine and pyridostigmine bromide interactions in the common marmoset Callithrix jacchus: Immunological and endocrinological effects.  (Hornby RJ, et al.  Int Immunopharmacol.  Dec 2006; 6(12): 1765-1779)
 
14. Effects of brief cutaneous JP-8 jet fuel exposures on time-course of gene expression in the epidermis.  (McDougal JN, et al.  Toxicol Sci.  Nov 3, 2006; [Epub ahead of print])
 
15. Incidence, etiology, and impact of diarrhea among deployed US military personnel in support of Operation Iraqi Freedom and Operation Enduring Freedom.  (Monteville MR, et al.  Am J Trop Med Hyg.  Oct 2006; 75(4): 762-767)
 
16. Predictors of exercise compliance in individuals with Gulf War veterans’ illnesses: Department of Veterans Affairs Cooperative Study 470.  (Mori DL, et al.  Mil Med.  Sep 2006; 171(9): 917-923)
 
17. Persistence of symptoms in veterans of the first Gulf War: 5-year follow-up.  (Ozakinci G, et al.  Environ Health Perspect.  Oct 2006; 114(10): 1553-1557)
 
18. Health in the Middle East:  no strong link between depleted uranium and cancer.  (Patel A.  BMJ.  Nov 4, 2006; 333(7575): 971.)
 
19. Uranium induces oxidative stress in lung epithelial cells.  (Periyakaruppan A, et al.  Arch Toxicol.  Nov 24, 2006; [Epub ahead of print])
 
20. Aluminum adjuvant linked to Gulf War illness induces motor neuron death in mice.  (Petrik MS, et al.  Neuromolecular Med.  2007; 9(1): 83-100)
 
21. Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of Interleukin 10.  (Qian L, et al.  J Neural Transm Suppl.  2006; Suppl (7): 367-371)
 
22. Neuropsychological sequelae from acute poisoning and long-term exposure to carbamate and organophosphate pesticides.  (Roldan-Tapia L, et al.  Neurotoxicol Teratol.  Aug 30, 2006; [Epub ahead of print])
 
23. Pyridostigmine, diethyltoluamide, permethrin, and stress: a double-blind, randomized, placebo-controlled trial to assess safety.  (Roy MJ, et al.  Mayo Clin Proc.  Oct 2006; 81(10): 1303-1310)
 
24. Gulf War syndrome:  the final chapter?  (Sartin JS.  Mayo Clin Proc.  Nov 2006; 81(11): 425-426)
 
25. A comparison of the postdeployment hospitalization experience of U.S. military personnel following service in the 1991 Gulf War, Southwest Asia after the Gulf War, and Bosnia.  (Smith B, et al.  J Occup Environ Med.  Dec 2006; 3(12): 660-670)
 
26. Pain in veterans of the Gulf War of 1991: a systematic review.  (Thomas HV, et al.  BMC Musculoskelet Disord.  Sep 20, 2006; 7:74)
 
27. Genotoxic effects of insecticides in current use on mucosal epithelial cells from human tonsil tissue.   (Tisch M, et al.  HNO.  Dec 6, 2006; [Epub ahead of print])  [Note: Non-English language publication]
 
28. In vivo effects of chronic contamination with depleted uranium on vitamin D(3) metabolism in rat.  (Tissandie E, et al.  Biochim Biophys Acta.  Oct 19, 2006; [Epub ahead of print])
 
29. Micronucleus studies in the peripheral blood and bone marrow of mice treated with jet fuels, JP-8 and Jet-A.  (Vijayalaxmi, et al.  Mutat Res.  Sep 19, 2006; 608(1): 82-87)
 
30. Seroepidemiology of selected zoonotic infections in Basra region of Iraq.  (Yacoub AA, et al.  East Mediterr Health J.  Jan-Mar 2006; 12(1-2): 112-118) 

Research on Evaluation/Treatment of Chronic Multisymptom Illnesses
 
1. Fibromyalgia, infection and vaccination: Two more parts in the etiological puzzle.  (Ablin JN, et al.  J Autoimmun.  Oct 27, 2006; [Epub ahead of print])
 
2. Posttraumatic stress disorder, tenderness, and fibromyalgia syndrome: are they different entities?  (Amital D, et al.  J Psychosom Res.  Nov 2006;  61(5): 663-669)
 
3. Probing the working memory system in chronic fatigue syndrome: a functional magnetic resonance imaging study using the n-back test.  (Caseras X, et al.  Psychosom Med.  Nov 1, 2006; [Epub ahead of print])
 
4. A pilot study of external qigong therapy for patients with fibromyalgia.  (Chen KW, et al.  J Altern Complement Med.  Nov 2006; 12(9): 851-856)
 
5. Multiple chemical sensitivities: a systematic review of provocation studies.  (Das-Munshi J, et al.  J Allergy Clin Immunol.  Sep 25, 2006; 118(6): 1257-1264 [Epub ahead of print])
 
6. A randomized, sham-controlled, proof of principle study of transcranial direct current stimulation for the treatment of pain in fibromyalgia.  (Fregni F, et al.  Arthritis Rheum.  Nov 28, 2006; 54(12): 3988-3998 [Epub ahead of print])
 
7. Differential efficacy of a cognitive-behavioral intervention versus pharmacological treatment in the management of fibromyalgic syndrome.  (Garcia J, et al.  Psychol Health Med.  Nov 2006; 11(4): 498-506)
 
8. Cognitive dysfunction in fibromyalgia and chronic fatigue syndrome: new trends and future directions.  (Glass JM.  Curr Rheumatol Rep.  Dec 2006; 8(6): 425-429)
 
9. Early adverse experience and risk for chronic fatigue syndrome: results from a population-based study.  (Heim C, et al.  Arch Gen Psychiatry.  Nov 2006; 63(11): 1258-1266)
 
10. Premorbid predictors of chronic fatigue.  (Kato K. et al.  Arch Gen Psychiatry.  Nov 2006; 63(11): 1267-1272)
 
11. Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins.  (Maes M, et al.  Neuro Endocrinol Lett.  Oct 2006; 27(5) [Epub ahead of print])
 
12. Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide.  (Ozgocmen S, et al.  Rheumatol Int.  May 2006; 26(7) 585-597)
 
13. Cognitive-behaviour therapy for chronic fatigue syndrome: comparison of outcomes within and outside the confines of a randomized controlled trial.  (Quarmby L, et al.  Behav Res Ther.  Oct 27, 2006; [Epub ahead of print])
 
14. Sleep characteristics of persons with chronic fatigue syndrome and non-fatigued controls: results from a population-based study.  (Reeves WC, et al.  BMC Neurol.  Nov 16, 2006; 6(1): 41 [Epub ahead of print])
 
15. Low-resolution electromagnetic brain tomography (LORETA) of monozygotic twins discordant for chronic fatigue syndrome.  (Sherlin L. et al.  Neuroimage.  Dec 12, 2006; [Epub ahead of print])
 
16. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study.  (Teitelbaum JE, et al.  J Altern Complement Med.  Nov 2006; 12(9): 857-862)
 

Back to Previous Research Updates